Thyroid cancer and lymph node metastases

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 615-618

  Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; lymph; thyroid

Indexed keywords

ARTICLE; ECHOGRAPHY; HUMAN; LYMPH NODE METASTASIS; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL; THYROID CANCER;

CARCINOMA, PAPILLARY; HUMANS; LYMPHATIC METASTASIS; NECK DISSECTION; PROGNOSIS; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 79953856899     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21804     Document Type: Article

References (56)

1. Ries LAG, Melbert D, Krapcho M, et al.: SEER Cancer Statistics review 1975-2004. National Cancer Institute. Bethesda, MD;, based on November 2006 SEER data submission, posted to the SEER website 2007.
2. Hundahl S, Fleming ID, Fremgeri AM, et al.: A National Cancer Database report on 53,856 cases of thyroid carcinoma treated in the US. Cancer 1988; 83: 2638-2648.
3. Fraker DL,: Radiation exposure and other factors that predispose to human thyroid neoplasm. Surg Clin North Am 1995; 75: 365-375.
4. Sipple RS, Caron N, Orlo OH,: An evidence-based approach to familial nonmedullary thyroid cancer: Screening, clinical management, and follow-up. World J Surg 2007; 31: 924-933. (Pubitemid 46716780)
5. Sturgeon C, Clark OH,: Familial thyroid cancer. Thyroid 2005; 15: 588-593.
6. Nikiforova MN, Kimura ET, Gandi M, et al.: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399-5404. (Pubitemid 37452745)
7. Xing M, Westra WH, Tufano RP, et al.: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-6379. (Pubitemid 41759286)
8. Kebebew E, Weng J, Bauer J, et al.: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-470. (Pubitemid 47312140)
9. Jossart G, Epstein HD, Shaver JK, et al.: Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. J Clin Endocrinol Metab 1996; 81: 3498-3504. (Pubitemid 26339906)
10. Mazzaferri EL,: What is the optimal initial treatment of low-risk papillary thyroid cancer and why is it controversial? Oncology 2009; 23: 579-588.
11. Grant CS, Hay ID, Gough IR, et al.: Local recurrence in papillary thyroid cancer: Is extent of surgical resection important? Surgery 1988; 140: 954-962. (Pubitemid 19011972)
12. Bilimoria KY, Bentrem DJ, Ko CY, et al.: Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007; 246: 375-384.
13. Robbins J, Merino MJ, Boice JD Jr., et al.: Thyroid carcinoma: A lethal endocrine neoplasm. Ann Intern Med 1991; 115: 133-147.
14. Noguchi S, Noguchi A, Murakami N,: Papillary carcinoma of the thyroid: I. Developing pattern of metastasis. Cancer 1970; 26: 1053-1061.
15. Attie JN, Khafif RA, Steckler RM,: Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg 1971; 122: 464-471.
16. Wada N, Duh QY, Sugino K, et al.: Lymph node metastases from 259 papillary thyroid microcarcinomas: Frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003; 237: 399-407. (Pubitemid 38176456)
17. Pereira JA, Jimeno J, Miguel J, et al.: Nodal yield, morbidity and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 2005; 138: 1095-1100.
18. Pellegriti G, Scollo C, Lumera G, et al.: Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm diameter: Study of 299 cases. J Clin Endocrinol Metab 2004; 89: 3713-3720. (Pubitemid 39071462)
19. Noguchi S, Murakami N, Yamashita H, et al.: Papillary thyroid carcinoma: Modified radical neck dissection improves prognostic. Ann Surg 1998; 133: 276-280. (Pubitemid 28154989)
20. Ito Y, Miyauchi A,: Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: Indications, benefits, and risks. World J Surg 2007; 31: 905-915. (Pubitemid 46716772)
21. Greb SKG, Hay ID,: Follicular thyroid cancer. Endocrinol Metab Clin North Am 1995; 24: 761-801.
22. Sadowski BM, Snyder SK, Lairmore TC,: Routine bilateral central lymph node clearance for papillary thyroid cancer. Surgery 2009; 146: 696-705.
23. White ML, Gauger PG, Doherty GM,: Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007; 31: 895-904. (Pubitemid 46716783)
24. Tisell LE, Nilsson B, Nolue J, et al.: Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996; 20: 854-859. (Pubitemid 26281914)
25. Cooper OS, Doherty GM, Haugen BR, et al.: Management guidelines for patients with thyroid nodule and differentiated thyroid cancer. Thyroid 2006; 16: 107-141.
26. Sherman S, Fagin J,: Why thyroid cancer? Thyroid 2005; 15: 303-304. (Pubitemid 40677398)
27. Kebebew E, Greenspan FS, Clark OH, et al.: Extent of disease, practice patterns for medullary thyroid cancer. J Am Coll Surg 2005; 200: 890-896. (Pubitemid 40744797)
28. Sywak M, Cornford L, Roach P, et al.: Routine level six lymphadenectomy reduces postoperative thyroglobulin level in papillary thyroid cancer. Surgery 2006; 140: 1000-1007. (Pubitemid 44937385)
29. Harwood J, Clark OH, Dunphy JE,: Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg 1978; 136: 107-112. (Pubitemid 8387088)
30. Cady B, Sedgwick CE, Meissner WA, et al.: Changing clinical, pathological, therapeutic and survival patterns in differentiated thyroid carcinoma. Ann Surg 1976; 184: 541-556.
31. Hay I, Grant CS, van Heerden JA,.: Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50 year period. Surgery 1992; 112: 1135-1147.
32. Spires JR, Robbins KT, Luna MA, et al.: Metastatic papillary carcinoma of the thyroid: The significance of extranodal extension. Head Neck Surg 1989; 11: 242-246. (Pubitemid 20052796)
33. Byar DP, Green SB, Dor P, et al.: A prognostic index for thyroid carcinoma: A study of the EDRTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 115: 1033-1041. (Pubitemid 9254743)
34. Mazzaferri EL, Young RL,: Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70: 511-518. (Pubitemid 11153883)
35. Harness JK, Organ CH Jr., Thompson NW,: Operative experience of U.S. general surgery residents with diseases of the adrenal glands, endocrine pancreas, and other less common endocrine organs. World J Surg 1996; 20: 885-890; discussion 890-1.
36. Schumann GF, Grim O, Wegener G, et al.: Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994; 18: 559-567; discussion 567-8.
37. Tennvall J, Biörklund A, Möller T, et al.: Prognostic factors of papillary, follicular and medullary carcinomas of the thyroid gland. Retrospective multivariate analysis of 216 patients with a median follow-up of 11 years. Acta Radiol Oncol 1985; 24: 17-24 (Pubitemid 15097822)
38. Yamashita H,: Occult microcancer and clinical cancer in thyroid cancer diagnosis and treatment. In: Thyroid cancer., Clark OH, Noguchi S, editors. St. Louis, MO: Quality Medical Publ, Inc.; 2000. pp. 105-126.
39. Lundgren CI, Hall P, Dickman PW, et al.: Clinically significant prognostic actors for differentiated thyroid carcinoma. Cancer 2006; 106: 524-531.
40. Zaudfudin V, Feurer ID, Griffin MR, et al.: The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008; 144: 1070-1078.
41. Hutter RV, Frazell EL, Foote FW Jr.:, Elective radical neck dissection: An assessment of its use with management of papillary thyroid cancer. CA Cancer J Clin 1970; 20: 87-93.
42. Henry JF, Gramatica L, Deizot A, et al.: Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998; 383: 162-169.
43. Grant CS, Stulak JM, Thompson GB, et al.: The risk and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006. IAES 2009.
44. Kim TY, Kim WB, Song JY, et al.: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005; 63: 588-593. (Pubitemid 41626756)
45. Xing M, Westra WH, Tufano RP,: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2009; 90: 6373-6379. (Pubitemid 41759286)
46. Kebebew W, Weng J, Bauer J, et al.: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-470. (Pubitemid 47312140)
47. Wagner PL, Moo TA, Arora N, et al.: The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma. Ann Surg Oncol 2008; 15: 2833-2841.
48. Gonzalez HE, Leiva A, Tobar H, et al.: Altered chemokine receptor expression in papillary thyroid cancer. Thyroid 2009; 19: 957-965.
49. Tanaka K, Kurebayashi J, Sohda M, et al.: The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence. Thyroid 2009; 19: 21-25.
50. Jonklaas J, Sarlis NJ, Litofsky D, et al.: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16: 1229-1242. (Pubitemid 46080167)
51. Shen WT, Ogawa L, Ruan D, et al.: Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg 2010; 145: 272-275.
52. Alvarado R, Sywak MS, Delbridge L, et al.: Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity. Surgery 2009; 145: 514-518.
53. Triponez F, Poder L, Zarnegar R, et al.: Hook needle-guided excision of recurrent differentiated thyroid cancer previously operated neck compartments: A safe technique for small non palpable recurrent disease. J Clin Endocrinol Metab 2006; 91: 4943-4947. (Pubitemid 44917331)
54. Sipple RSM, Elaraj DM, Poder L, et al.: Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg 2009; 33: 434-439.
55. Keleman PR, Van Herle AJ, Giuliano AS,: Sentinel lymphectomy in thyroid malignant neoplasms. Arch Surg 1998; 133: 288-292. (Pubitemid 28154991)
56. Kim WG, Yoon JH, Kim WB, et al.: Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrent in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93: 4683-4689.